Additionally, its immunomodulatory effects on the tumor microenvironment (TME) establish a theoretical foundation for combination with PD-1/PD-L1 or CTLA-4 inhibitors, potentially overcoming immune tolerance in certain patients (78). This evidence concerns the gene CTLA4 and neoplasm.